New: Introducing the Finviz Futures Map

Learn More

Amgen Inc. (AMGN)'s Experimental Obesity Drug MariTide Shows Up to 20% Weight Loss Potential

By Laiba Immad | September 02, 2025, 3:29 AM

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Amgen Inc. is one of them,

Amgen Inc. (NASDAQ:AMGN), the California-based biotech giant, continues to strengthen its leadership in cardiovascular, oncology, respiratory, and rare diseases while expanding into new therapeutic frontiers.

In Q2 2025, the company posted a 9% year-over-year revenue increase, fueled by double-digit growth across 15 core products. Investment in R&D climbed 18%, with the company prioritizing high-impact areas like obesity, cardiovascular disease, and oncology. A $900 million manufacturing expansion in Ohio will support future supply and create hundreds of new jobs, underscoring the business’s commitment to scaling its pipeline.

The spotlight remains on MariTide, Amgen Inc. (NASDAQ:AMGN)’s experimental obesity drug designed to target both GLP-1 and GIP receptors for potentially superior weight-loss outcomes. Key Phase 2 trial results are expected in late 2025, including studies in both obesity and type 2 diabetes. Early data suggests patients could achieve weight loss of up to 20%, positioning MariTide as a potential disruptor in a market projected to exceed $150 billion globally.

Amgen Inc. (AMGN)’s Experimental Obesity Drug MariTide Shows Up to 20% Weight Loss Potential

Regulatory and clinical momentum also continues across Amgen Inc. (NASDAQ:AMGN)’s portfolio. In August 2025, Repatha gained expanded FDA approval for adults at elevated risk of major cardiovascular events, while Tezspire posted 46% sales growth year-over-year as adoption in severe asthma accelerates. Meanwhile, biosimilars revenue jumped 40%, strengthening margins and expanding access to affordable therapies.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.

Mentioned In This Article

Latest News